Resources
- sort by:
- Relevance
- Date
- Popularity
- Threat to asthma drug winds GSK.
- Sales of GlaxoSmithKline's GSK asthma drug, Advair, could be hit by product-labelling issues. The US Food and Drug Administration FDA has asked drug companies to place 'black box' warnings on the labels of three asthma products containing salmet Sales of GlaxoSmithKline's GSK asthma drug, Advair,...
- Research articles 2005-11-25
- Genentech and Novartis Suffer Setback for Xolair.(asthma drug)(Brief Article)
- IN A MAJOR setback for Genentech Gne,, Food & Drug Administration FDA has delayed the approval of Xolair omalizumab, an allergy and asthma drug being developed in partnership with Novartis AG and Tanox Inc. Launch of the drug was originally IN A MAJOR setback...
- Research articles 2001-07-16
- HEALTH BEAT: Where The Air Is Clear; Denver Hospital, founded out of 'tikkun olam,' develops new asthma drug.
- Kritz, Francesca Lunzer The Jewish Week 03-17-2000 HEALTH BEAT: Where The Air Is Clear; Denver Hospital, founded out of `tikkun olam,' develops new asthma drug. FRANCESCA LUNZER KRITZ Late last year the New England Journal of Medicine published a...
- Research articles 2000-03-17
- FDA's Asthma Drug Warning Comes After Complaints About Testing Facility
- The FDA's new requirement for tighter warnings on a range of asthma drugs will not come as a surprise to Dr. Robert Davidson, a former asthma drug clinical trial researcher, who has repeatedly alleged that asthma drugs tested at a faciluty he once worked at were riddled with patients who...
- Blog posts 2009-06-15
- EU health authorities approve use of AstraZeneca's asthma drug in children
- NORDIC BUSINESS REPORT-3 January 2002-EU health authorities approve use of AstraZeneca's asthma drug in children C1994-2002 M2 COMMUNICATIONS LTD http://www.m2.com
- Research articles 2002-01-03
- Tianyin Wins Approval for Asthma Drug
- ChinaBio Today submits: Tianyin Pharmaceutical, Co. (TYNP.OB) will add to its list of modernized traditional Chinese medicines the recently SFDA-approved Laonian Kechuan Tablets, a new drug for the company which was approved with a dose of 0.25 gram/tablet. The product is aimed at asthma sufferers who are 60 years...
- External links 2008-09-11
- MedImmune asthma drug promising
- MedImmune Inc.'s next round of human testing could confirm that an experimental drug could treat and prevent asthma.
- Research articles 2003-05-20
- Rockwood to study potential of nasal-spray asthma drug
- Rockwood Clinic PS, of Spokane, is researching the potential of an anti-viral nasal spray to reduce an asthma patient's vulnerability to additional health complications triggered by the common cold. The compound used in that spray, pleconaril, was studied in its oral form at least seven years ago for possible treatment...
- Research articles 2007-02-08
- Schering-Plough, Genome Link for Asthma Drug
- SCHERING-PLOUGH CORPORATION, Madison, N.J., and Genome Therapeutics Corporation, Waltham, Mass., will collaborate in the use of genomics to discover new therapeutics for treating asthma. Total value of the deal could approach $67 million, $22.5 mi SCHERING-PLOUGH CORPORATION, Madison, N.J., and Genome Therapeutics ...
- Research articles 1996-12-30
- AstraZeneca tours for pediatric asthma
- ASTRAZENECA HIT the road at the end of August for a national direct marketing tour to raise awareness of pediatric asthma and to promote its asthma drug Pulmicort Respules and its Web site, www.everydaykidz.com.
- Research articles 2005-10-01
- Houston-Based Firm Makes Deal with Schering-Plough to Develop Asthma Drug.(Knight Ridder/Tribune Business News)
- Jul. 11--Texas Biotechnology, a Houston company that develops drugs for vascular diseases, said Monday it has signed a multimillion-dollar research collaboration and license agreement with Schering-Plough to develop a treatment for asthma. Jul. 11--Texas Biotechnology, a Houston company that develops drugs for vascular...
- Research articles 2000-07-11
- The 340B Prime Vendor Program Adds AstraZeneca's Asthma Drug SYMBICORT(R) to Its List of Branded Drugs Available for Participants
- The 340B Prime Vendor Program PVP, managed by Apexus Inc., announced today that SYMBICORT® (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler pMDI is now available to PVP participants for the long-term maintenance treatment of asthma in patients 12 years of age and older.
- Research articles 2007-09-27
- Allergy & Asthma Network Mothers of Asthmatics Supports FDA's Alert to People with Asthma -- Take Action to Avoid Treatment Delays
- FAIRFAX, Va., March 14 /U.S. Newswire/ -- The Allergy & Asthma Network Mothers of Asthmatics AANMA notes the Food and Drug Administration's (FDA's) recent alert to asthma patients and the health care community regarding the temporary disruption in tFAIRFAX, Va., March 14 /U.S. Newswire/ -- The Allergy & Asthma Network...
- Research articles 2006-03-14
- Asthmatx Completes Enrollment in Pivotal Study of Bronchial Thermoplasty: Milestone Reached in Advancement of Bronchial Thermoplasty, an Innovative Non-Drug Procedure for Asthma
- Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma, announced today the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair® Bronchial Thermoplasty System. Bronchial Thermoplasty is a non-drug...
- Research articles 2007-05-21
- Critical Therapeutics Announces FDA Approval of ZYFLO® for the Prevention and Chronic Treatment of Asthma; Oral Drug Blocks the Production of Mediators That Can Trigger Asthma Symptoms
- LEXINGTON, Mass. -- Critical Therapeutics, Inc. (Nasdaq: CRTX) announced today that the U.S. Food and Drug Administration FDA has approved the Company's supplemental New Drug Application sNDA to manufacture and market ZYFLOR zileuton tablets, which is indicated for the prevention and chronic treatment of asthma in patients 12 years of...
- Research articles 2005-09-28
- Novartis Faces Setback for Zomaril.(additional clinical trials planned)(Brief Article)
- ON THE HEELS of a product delay for its allergy drug and asthma drug Xolair omalizumab, Novartis AG reports that it will plan additional clinical trials for its schizophrenia drug Zomaril iloperidone. Novartis and its development partner ...
- Research articles 2001-07-30
- SKYEPHARMA (SKP).
- Skyepharma's shareholders must be breathing a sigh of relief after news that the drug delivery specialist has completed Phase III trials with AstraZeneca for an environmentally friendly version of inhaled asthma drug Pulmicort. The European drug indu Skyepharma's shareholders must be breathing a sigh of relief...
- Research articles 2004-07-16
- Pfizer's asthma pipeline boasts attractive therapeutic overlap. (Markets: Pharmaceuticals & Fine Chemicals).(Brief Article)
- PFIZER INC. is poised to penetrate the lucrative market for treating asthma and chronic obstructive pulmonary disease COPD, with not just one, but two promising drugs, generating industry buzz. Its copromotional drug Spiriva tiotropium recently PFIZER INC. is poised to penetrate the lucrative market...
- Research articles 2002-09-16
- GSK ends Serevent study after FDA analysis
- An interim analysis of a large safety study of GlaxoSmithKline's asthma drug Serevent salmeterol xinafoate "suggests that the drug may be associated with an increased risk of life-threatening asthma episodes or asthma-related deaths, particularly in some patients," the FDA said Jan. 23. GlaxoSmithKline stopped the study mostly due to difficulties...
- Research articles 2003-03-01
- Altana suffers new setback in launch of blockbuster asthma drugs
- BAD HOMBURG, Germany AFP — German drug maker Altana said that it had postponed its application for approval of its new asthma treatment Roflumilast in the United States in order to undertake additional clinical trials on the drug. Roflumilast, a phosphodiesterase inhibitor being studied for the treatment of chronic...
- Research articles 2004-10-28
- << Previous
- page 1 of 6
- Next >>
Presented by American Express